# STRIVE (GRAIL breast screening cohort)

Source: https://onco.cc/trials/strive-grail/  
OnCo record `strive-grail` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A cohort of about 100,000 women having mammograms whose blood GRAIL stored to check its multi-cancer test against the cancers that appeared over the next year.

## Summary

STRIVE (NCT03085888) is an observational study sponsored by GRAIL, Inc. Its registry purpose is to evaluate the pre-specified GRAIL test for invasive cancers, including blood cancers, diagnosed within one year of the first blood draw, and to refine the classifier and its cut-offs.

The registry record, read on 29 October 2026, gives its status as completed, with 99,481 participants enrolled, a start on 28 February 2017 and primary completion on 30 June 2022.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-10-29
- Also known as: STRIVE; GRAIL-002
- Registry id: NCT03085888
- Phase: observational
- Setting: Women having screening mammography in the United States, giving blood at the time of the mammogram so a cell-free DNA test could be evaluated against cancers diagnosed in the following year
- Sponsor: GRAIL, Inc.
- Enrolled: 99481

## Sources

- ClinicalTrials.gov NCT03085888: https://clinicaltrials.gov/study/NCT03085888

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [Galleri](https://onco.cc/drugs/galleri/)
- companies: [GRAIL](https://onco.cc/companies/grail/)
- key papers: [Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA](https://onco.cc/key-papers/paper-liu-ccga2-methylation-ann-oncol-2020/)

---
JSON: https://onco.cc/api/v1/entities/strive-grail.json